The US Food and Drug Administration (FDA) has granted approval for Roche's Gazyva/ Gazyvaro (obinutuzumab) to treat adult ...

Eventual tapering and withdrawal of steroids in patients with lupus nephritis is recommended to minimize the drugs' adverse ...

The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease ...

With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...

The drug is the only medicine of its kind proven to help patients with lupus nephritis regain full kidney response, the ...

Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease ...

The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...

Lupus continues to carry a heavy burden despite advances in immunosuppressive therapy warranting complementary care ...

Researchers found that urine protein profiles reflect kidney inflammation and scarring in lupus nephritis, pointing to a ...

Roche has received FDA approval for its antibody treatment Gazyva to be used in combination with standard therapy for adults with active lupus ...

The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research ...